Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence.

In gemcitabine-treated early-onset disease, TP53 mutations were present in 86.7% of tumors, compared with 40.0% in non-treated early-onset tumors ( Table S5 ), representing a strong trend that did not meet statistical significance in this small subgroup ( p = 0.0726).

also in 5,725 other papers

Additional RTK/RAS-axis genes (e.g., EGFR, ERBB3, FGFR3, MET, ROS1, ALK) appeared at low frequency among treated late-onset tumors but did not reach statistical significance versus non-treated disease ( Table S2 ).

also in 111,027 other papers